Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
13,481 total articles
Biofrontera Inc. reported a 17% increase in Q1 2026 revenues to $10.1 million with gross margins improving to 80%. The company reduced cash consumption substantially and improved adjusted EBITDA margins. Key clinical milestones include FDA acceptance of a supplemental NDA for superficial basal cell carcinoma (sBCC) with a PDUFA date set for Septemb…
FitLife Brands, Inc. announced first quarter 2026 financial results with total revenue rising 59% year-over-year to $25.3 million, fueled primarily by the acquisition of Irwin which contributed significantly to wholesale revenue growth. However, gross margin declined to 37.6% due to lower-margin Irwin business, and net income decreased to $1.7 mill…
Merlin, Inc., an aerospace and defense technology company specializing in autonomous flight systems, reported its Q1 2026 financials following its recent public listing. Key developments include successful automated takeoffs, advancement in civil certification with FAA and New Zealand CAA, progress on a $105 million military contract for C-130J aut…
FTI Consulting's 2026 Hospital Operations Outlook Survey reveals that 92% of US hospital leaders anticipate significant financial challenges ahead due to affordability, policy shifts, and evolving care delivery models. Key operational pressures include workforce shortages, physician recruitment difficulties, and data security concerns. Despite adva…
Cytokinetics, Inc., a specialty cardiovascular biopharmaceutical company, will host the third annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on May 29, 2026, in San Francisco, showcasing advancements in muscle biology research related to cardiac and skeletal muscle as well as emerging treatment modalities. The event wil…
Nuvectis Pharma, a clinical-stage biopharmaceutical company developing precision oncology medicines, announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company will present its clinical-stage drug candidate NXP900, which is targeting SRC family kinases for cancer treatment, with Phase 1…
Intuitive Machines, Inc. announced its definitive agreement to acquire Goonhilly Earth Station Ltd and its US-based COMSAT division. This acquisition is set to significantly enhance Intuitive Machines' integrated space-to-Earth communications network by adding 44 antennas and expanding capacity for deep space communications, data relay, and Positio…
Cellectar Biosciences reported positive 12-month follow-up data for iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia from their Phase 2b CLOVER WaM study, achieving key efficacy endpoints. The company secured up to $140 million in financing to support a Phase 3 confirmatory trial and FDA accelerated approval filing. Additionall…
Crown Crafts, Inc. announced a quarterly cash dividend of $0.08 per share on its Series A common stock, payable July 2, 2026. This move demonstrates the company's ongoing commitment to returning value to shareholders amid its operations in infant and juvenile consumer products.
Cabaletta Bio reported progress in its rese-cel CAR T cell therapy clinical trials for autoimmune diseases, announced a 10-year commercial supply agreement with Cellares for automated, cost-effective manufacturing, and shared positive preliminary clinical data showing drug-free clinical responses. The company also raised $150 million in gross proce…
Invivyd, Inc. announced a 22% year-over-year increase in net product revenue for PEMGARDA® in Q1 2026, totaling $13.7 million. The company reported favorable in vitro neutralization activity of its pemivibart and VYD2311 antibodies against the Omicron BA.3.2.2 variant. The DECLARATION Phase 3 trial for VYD2311 has completed initial enrollment, with…
Chicago Atlantic BDC, Inc., a specialty finance company focused on lending to privately held middle-market and cannabis companies, announced a $0.34 per share cash dividend for the quarter ending June 30, 2026. The company aims to maximize risk-adjusted returns through its investment strategy and is regulated as a business development company.
Akamai Technologies announced its definitive agreement to acquire LayerX, a provider of browser-based AI usage control and secure enterprise browser technology, for approximately $205 million. This acquisition aims to enhance Akamai's Zero Trust security solutions by extending protection to browser-level AI interactions, addressing a critical secur…
EyePoint, Inc. announced the independent Data Safety Monitoring Committee (DSMC) has completed its third positive review of the Phase 3 trials for DURAVYUTM, a sustained-release intravitreal treatment for wet age-related macular degeneration (wet AMD). The DSMC recommends continuation of the ongoing LUGANO and LUCIA trials without modifications, ba…
Fiserv has launched agentOS, an agentic AI operating system designed to help banks and credit unions deploy, manage, and scale AI agents securely across key workflows. Built into Fiserv's platforms and developed with six financial institutions, agentOS features a native marketplace with first-party and third-party AI agents targeting risk managemen…
Destination XL Group, Inc., a leading retailer specializing in Big + Tall men's apparel, will release its first quarter fiscal 2026 financial results before market open on May 28, 2026. The company will host a conference call and webcast to discuss the results, with details provided for investor participation.
CAMP4 Therapeutics announced new preclinical data showing that their lead candidate, CMP-002, significantly improves seizure threshold and severity in a SYNGAP1 haploinsufficient mouse model. These results extend previous evidence of neurodevelopmental benefits and support the planned initiation of a Phase 1/2 clinical trial in SYNGAP1-related diso…
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company developing treatments for gout and kidney diseases, announced a $5 million public offering of common shares and pre-funded warrants priced at $1.88 per share. The offering is subject to customary regulatory approvals and is intended to support the advancement of their clinical pi…
Autolus Therapeutics reported first quarter 2026 net product revenue of $26.2 million, driven by the successful US and UK launches of AUCATZYL, its CAR T-cell therapy for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The company achieved positive gross margin for its ALL business for the first time and is impleme…
Aveanna Healthcare Holdings Inc. announced robust financial results for Q1 2026, highlighting a 15.9% revenue increase to $647.9 million and a 25.2% rise in Adjusted EBITDA to $84.4 million compared to the prior year period. The company raised its 2026 revenue guidance to $2.56-$2.58 billion and Adjusted EBITDA to $328-$332 million, reflecting stro…
Americold has announced a strategic expansion of its cold chain logistics services with PLUS, a Netherlands-based supermarket cooperative. Americold will operate a centralized frozen product distribution center in Barneveld, streamlining PLUS's frozen supply chain across its 440 stores to enhance efficiency and service. This move highlights Americo…
American Shared Hospital Services reported a 15.9% increase in revenue for Q1 2026 driven by expansion in direct patient care services and increased procedure volumes at its Rhode Island and Puebla radiation therapy centers. Gross margins improved by 36.7%, and adjusted EBITDA rose 18.4%. Operating loss narrowed compared to the prior year period, s…
NRx Pharmaceuticals, a clinical-stage biopharmaceutical company focused on CNS disorders, will release its Q1 2026 financial results on May 18, 2026, followed by a conference call. The company is developing therapeutics targeting suicidal depression and related conditions with drug candidates NRX-100 and NRX-101, which have received Fast Track and …
Tonix Pharmaceuticals announced a poster presentation at ISPOR 2026 featuring a retrospective analysis of U.S. real-world claims data on fibromyalgia patients. This follows the August 2025 FDA approval and November 2025 U.S. commercial launch of TONMYA® (cyclobenzaprine HCl sublingual tablets), the first new fibromyalgia treatment in over 15 years.…
Aya Gold & Silver Inc. announced a record Q1 2026 financial performance with revenues of $117M, a 247% increase year-over-year, net income growth of 600%, and strong operating cash flow of $70M. Operationally, consolidated silver equivalent production rose 40% YoY to 1.5M ounces, despite some weather disruptions at the Zgounder mine. The company ad…
